Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12
- bone marrow
- cell therapy
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26487
The term Products expressly excludes Thalidomide analogs. The product is currently is under review by the European Medicines Agency (EMEA) to treat patients with newly diagnosed multiple myeloma. Multiple myeloma (also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease after Otto Kahler) is a type of cancer of plasma cells which are immune system cells in bone marrow that produce antibodies. Myeloma is regarded as incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. Myeloma is part of the broad group of diseases called hematological malignancies.
IPSCIO Record ID: 70123
Multiple Myeloma is a severe and incurable malignant hematological cancer of plasma cells.
We were granted an Orphan-drug designation from the FDA in May 2011, for rHuEPO.
IPSCIO Record ID: 203418
The term product shall mean any article of manufacture, substance, material, chemical, formulation or composition for use in the Field which is or includes Thalidomide as an active ingredient, including, without limitation, a composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s). The Product expressly excludes Thalidomide analogs.
THALOMID(R) (thalidomide), Licensee's lead product is currently marketed for the treatment of erythema nodosum leprosum, or ENL, but more widely used off-label for treating multiple myeloma and other cancers.
Erythema nodosum leprosum is one of the most frequently used terms in the science of leprosy. It is an immune-mediated complication of leprosy presenting with inflammatory skin nodules. Immune complex production and deposition as well as complement activation have long been regarded as the principal etiology of ENL. ENL is characterised by an inflammatory infiltrate of neutrophils with vasculitis. There is deposition of immune complexes and complement together with Mycobacterium leprae antigens in the skin.
IPSCIO Record ID: 271809
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell which normally produces antibodies.
IPSCIO Record ID: 26020
Thalidomide means the chemical described as 2-(2,6- Dioxo-3-piperidinyl)-lH- isoindole-1,3(2H)-dione
Thalidomide Analog means and includes any and all analogs, metabolites, precursors, and hydrolysis products of Thalidomide, and all stereoisomers of each of the foregoing, including without limitation (a) all such compounds disclosed, generically or specifically, or claimed by any of the Analog Patents, (b) Amino Thalidomide and all stereoisomers and metabolites thereof; and (c) Revimid, and all stereoisomers and metabolites thereof.
Thalidomide is used along with dexamethasone to treat multiple myeloma in people who have been recently found to have this disease. It is also used alone or with other medications to treat and prevent skin symptoms of erythema nodosum leprosum (ENL; episodes of skin sores, fever, and nerve damage that occur in people with Hansen's disease [leprosy]). Thalidomide is in a class of medications called immunomodulatory agents. It treats multiple myeloma by strengthening the immune system to fight cancer cells. It treats ENL by blocking the action of certain natural substances that cause swelling.
IPSCIO Record ID: 226067
LICENSED PATENT RIGHTS
1. PCT/US2012/049911 (WO2013022919A1)
2. USSN 61/521,287
3. USSN 14/237,494
4. Chinese Patent Application No. 201280048718; Pre-grant Publ. No. 103930166
1. Assignment document from University of Pittsburgh to inventors (Patent family of USSN 14/237,494).
2. Assignment document from Inventors to Dr. Xiang-Qun Xie (Patent family of USSN 14/237,494) .
3. Assignment document from Dr. Xiang-Qun Xie to ID4Pharma, LLC (Patent family of USSN 14/237,494).
Licensor have developed novel chemical compounds (e.g., OXS-4235) which inhibit osteoclastic bone destruction in multiple myeloma.
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies.
The drug is a P62-ZZ chemical inhibitor intended for use as a treatment for multiple myeloma.
IPSCIO Record ID: 3282
Licensee field is diagnostics in Multiple myeloma, or MM, a hematologic, or blood, cancer that develops in the bone marrow and specifically affects the plasma cells of the bone marrow.
The Licensee Licensed field includes applications to malignant and non-malignant human or animal pathologies, including but not limited to determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen. These uses, patent, and technology rights exclude using FISH, which is Licensed to a third party.
IPSCIO Record ID: 3283
shall have the right to grant sublicenses consistent with this Agreement.
Diagnosis and classification of multiple myeloma
United States Patent 7,308,364
Diagnosis of multiple myeloma on gene expression profiling
IPSCIO Record ID: 383557
MSC shall mean human cells that are capable of differentiation into more than one mesenchymal lineage.
Product means any product or composition that contains MSC and/or any process or service performed with respect to recovery, expansion, maintenance, purification, storage, production, formulation or use of MSC.
The patents include
— Monoclonal antibodies specific for marrow-derived mesenchymal cells;
— Uses for non-autologus mesenchymal stem cells;
— Osteoporosis bond regeneration;
— Mesenchymal stem cells for prevention and treatment of immune responses in transplantation;
— Mesenchymal stem cells as immunosuppressants;
— Regulation of Hema topoietic stem cell differentiation by the use of human mesenchymal stem cells;
— Uses of fibroblasts or supernatants from fibroblasts for the suppression of immune responses in transplantation.
Hematologic malignancies are cancers that begin in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. There are three main types of hematologic malignancies leukemia, lymphoma and multiple myeloma.
IPSCIO Record ID: 3921
MM is a severe plasma cell malignancy characterized by the accumulation and proliferation of clonal plasma cells in the marrow, leading to the gradual replacement of normal hematopoiesis.
IPSCIO Record ID: 332232
Know-How License Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under Licensorâ€™s rights in and to the Captisol Data Package and Product Know-How, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.
US Serial Number 12/790,724
Compound means that certain pharmaceutical compound known as melphalan, including all of its optical isomers, and salt, ester, and polymorphic forms.
US Patent #5,376,645 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US Patent #7,629,331 – Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US Patent #7,635,773 – Sulfoalkyl ether cyclodextrin compositions
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.
IPSCIO Record ID: 25826